ELAN Stock — Elanco Animal Health Incorporated: Cash, EV, Pipeline

Share price

$22.42

Market cap

$11,201.5M

Cash

$530.0M

Enterprise value

$14,334.5M

Balance sheet

Cash	$530.0M
Debt	$3,663.0M
Net cash	-$3,133.0M
Enterprise value	$14,334.5M
Basic shares	499.5M shares
Fully diluted shares	528.5M shares
Fully diluted market cap	$11,849.5M
Cash per share	$1.06

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ELAN daily closes…

Loading price history…

Pipeline assets

Zenrelia

Approved · Active Modality: small molecule (once-daily oral tablet)

Target JAK

Indications

Pruritus and atopic dermatitis in dogs (Approved)

Status note FDA approval September 2024; launched in U.S. and also commercialized in Australia, Brazil, Canada, EU, Japan and U.K.

Credelio Quattro

Approved · Active Modality: chewable tablet

Indications

Fleas, ticks, heartworms, roundworms, hookworms and three species of tapeworms in dogs (Approved)

Status note FDA approval October 2024; launched January 2025; conditional approval for treatment of New World screwworm (December 2025).

Befrena

Approved · Active Modality: monoclonal antibody (injection)

Target IL-31

Indications

Canine allergic and atopic dermatitis (Approved)

Status note USDA approval December 2025; phased launch initiated second quarter 2026.

AdTab

Approved · Active Modality: chewable tablet

Indications

Flea and tick treatment for dogs and cats (Approved)

Status note Approved and launched in the U.K. (April 2025).

lotilaner royalty interest

Approved · Active Modality: ophthalmic solution

Aliases lotilaner ophthalmic solution 0.25% (marketed by Tarsus as XDEMVY)

Partnerships Tarsus Pharmaceuticals (license agreement); Blackstone (May 2025 purchase and sale agreement for rights to proceeds from qualifying future U.S. royalties and certain global sales milestones for $295M; Elanco retains ex-U.S. royalties and U.S. royalties after August 24, 2033)

Indications

Demodex blepharitis (human) (Approved)

Status note Royalty/milestone interest in human health application of lotilaner marketed by Tarsus as XDEMVY; Elanco retains rights to royalties/milestones from future expansion of lotilaner in other human health applications.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	0	-20,000	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ELAN — Elanco Animal Health Incorporated

Balance sheet

Price history

Pipeline assets

Institutional holders